# Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

> **NCT00476099** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 828 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI
- **DRUG:** Budesonide 200 µg plus formoterol 6 µg DPI
- **DRUG:** Formoterol 12 µg DPI

## Key facts

- **NCT ID:** NCT00476099
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-08
- **Final completion:** 2008-11
- **Target enrollment:** 828 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00476099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00476099, "Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00476099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*